Gemcitabine hydrochloride
Based on 290 publication(s) in Google Scholar
Gemcitabine Hydrochloride (LY 188011 Hydrochloride) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine Hydrochloride inhibits DNA synthesis and repair, resulting in autophagyand apoptosis.
For research use only. We do not sell to patients.
- Purity: 99.89%
- CAS No.: 122111-03-9
- Formula: C9H12ClF2N3O4
- Molecular Weight:299.66
-
Storage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light)
Publications Citing Use of MedChemExpress (MCE) Gemcitabine hydrochloride
More- Signal Transduct Target Ther. 2025 Dec 15;10(1):406. [Abstract]
- Nat Med. 2024 Mar;30(3):749-761. [Abstract]
- Nature. 2019 Oct;574(7777):264-267. [Abstract]
- J Clin Oncol. 2026 Mar 2.
- Mol Cancer. 2024 Sep 30;23(1):215. [Abstract]
- Mol Cancer. 2024 Apr 29;23(1):86. [Abstract]
- Mol Cancer. 2024 Jan 10;23(1):12. [Abstract]
- Mol Cancer. 2023 Dec 4;22(1):195. [Abstract]
- Adv Mater. 2025 Jul 4:e2505231. [Abstract]
- Adv Mater. 2021 May;33(18):e2100949. [Abstract]
- Cell Res. 2020 Jul;30(7):574-589. [Abstract]
- Gastroenterology. 2021 Nov;161(5):1601-1614.e23. [Abstract]
- Cancer Commun (Lond). 2025 May 29. [Abstract]
- Nat Metab. 2025 Nov 13. [Abstract]
- Cancer Res. 2023 Sep 15;83(18):3059-3076. [Abstract]
- Hepatology. 2019 May;69(5):1995-2012. [Abstract]
- Nat Commun. 2026 May 28.
- Nat Commun. 2025 Jul 17;16(1):6592. [Abstract]
- Nat Commun. 2024 Oct 2;15(1):8540. [Abstract]
- Acta Pharm Sin B. 2026 Mar 2.
- Acta Pharm Sin B. 2023 Oct;13(10):4253-4272. [Abstract]
- Sci Transl Med. 2021 Jan 20;13(577):eaba7401. [Abstract]
- Adv Sci (Weinh). 2026 Jul;13(37):e75216. [Abstract]
- Adv Sci (Weinh). 2026 Feb 3:e16660. [Abstract]
- Adv Sci (Weinh). 2025 May 20:e01042. [Abstract]
- Adv Sci (Weinh). 2024 Nov 28:e2407519. [Abstract]
- Adv Sci (Weinh). 2025 Jan 21:e2409173. [Abstract]
- Adv Sci (Weinh). 2024 Aug 23:e2400156. [Abstract]
- Adv Sci (Weinh). 2023 Nov;10(33):e2302498. [Abstract]
- Adv Sci (Weinh). 2023 Oct;10(30):e2303872. [Abstract]
- Adv Sci (Weinh). 2023 Apr;10(12):e2206004. [Abstract]
- Adv Sci (Weinh). 2022 May;9(15):e2105894. [Abstract]
- J Clin Invest. 2024 Mar 7;134(10):e172716. [Abstract]
- Theranostics. 2021 Mar 24;11(12):5650-5674. [Abstract]
- Chem Eng J. 2024 Sep 1.
- Chem Eng J. 2023 Nov 17, 147466.
- J Adv Res. 2025 Nov 5:S2090-1232(25)00874-4. [Abstract]
- J Adv Res. 2025 Oct 16:S2090-1232(25)00818-5. [Abstract]
- Biomaterials. 2022 Oct:289:121800. [Abstract]
- J Exp Clin Cancer Res. 2023 May 4;42(1):111. [Abstract]
- J Exp Clin Cancer Res. 2022 Oct 5;41(1):293. [Abstract]
- J Exp Clin Cancer Res. 2021 Nov 25;40(1):373. [Abstract]
- J Nanobiotechnology. 2022 Jul 6;20(1):315. [Abstract]
- Sci Adv. 2026 Jun 26;12(26):eadz3351. [Abstract]
- Sci Adv. 2024 Dec 13;10(50):eadq4274. [Abstract]
- Sci Adv. 2024 Jul 5;10(27):eadl1197. [Abstract]
- Mol Ther. 2025 Sep 10:S1525-0016(25)00732-4. [Abstract]
- Redox Biol. 2024 May 17:73:103200. [Abstract]
- Redox Biol. 2021 Jan;38:101807. [Abstract]
- J Control Release. 2026 Jul 10:395:114990. [Abstract]
- J Control Release. 2023 Sep:361:161-177. [Abstract]
- Research (Wash D C). 2025 Jul 30:8:0809. [Abstract]
- J Exp Med. 2026 Apr 6;223(4):e20250978. [Abstract]
- Cell Rep Med. 2026 Feb 17;7(2):102613. [Abstract]
- Cell Rep Med. 2025 Sep 19:102357. [Abstract]
- Cell Rep Med. 2025 Apr 2:102053. [Abstract]
- J Immunother Cancer. 2024 Sep 4;12(9):e009318. [Abstract]
- Cell Rep Med. 2023 Oct 17;4(10):101234. [Abstract]
- Cell Rep Med. 2023 Feb 21;4(2):100911. [Abstract]
- Pharmacol Res. 2024 May 9:204:107208. [Abstract]
- Mater Today Bio. 2026 May 6:38:103195. [Abstract]
- Clin Cancer Res. 2026 Jan 21. [Abstract]
- Mater Today Bio. 2025 Jul 28:34:102153. [Abstract]
- Cancer Lett. 2026 Feb 4;642:218300.
- Cancer Lett. 2026 Apr 1:642:218300. [Abstract]
- Cancer Lett. 2025 Apr 16:217726. [Abstract]
- Cancer Lett. 2025 May 28:618:217633. [Abstract]
- Cancer Lett. 2024 Nov 28:605:217284. [Abstract]
- Cancer Lett. 2024 Apr 10:587:216696. [Abstract]
- Cancer Lett. 2023 Feb 1:554:216023. [Abstract]
- Cancer Lett. 2022 Jun 28;536:215651. [Abstract]
- Int J Biol Sci. 2022 Jul 4;18(11):4301-4315. [Abstract]
- Int J Biol Sci. 2022; 18(1):43-64.
- Cell Death Dis. 2026 Jun 25. [Abstract]
- Cell Death Dis. 2026 Apr 3;17(1):449. [Abstract]
- Cell Death Dis. 2026 Feb 23;17(1):247. [Abstract]
- Acta Biomater. 2025 Aug 27:S1742-7061(25)00640-3. [Abstract]
- Cell Death Dis. 2025 Aug 6;16(1):592. [Abstract]
- Cell Death Dis. 2025 Jul 15;16(1):526. [Abstract]
- Cell Death Dis. 2025 Jul 4;16(1):492. [Abstract]
- Cell Death Dis. 2025 Jan 18;16(1):28. [Abstract]
- Acta Biomater. 2023 Jul 1:164:407-421. [Abstract]
- Genes Dis. 2026 Mar 19.
- Proc Natl Acad Sci U S A. 2026 May 5;123(18):e2601788123. [Abstract]
- Cell Commun Signal. 2025 Nov 27;23(1):513. [Abstract]
- Chin Chem Lett. 2017 March.
- Int J Biol Macromol. 2025 Dec;334(Pt 1):148793. [Abstract]
- View. 2023 Nov 15.
- Acta Pharmacol Sin. 2024 Apr;45(4):844-856. [Abstract]
- Phytomedicine. 2025 Oct 8:148:157389. [Abstract]
- Phytomedicine. 2024 Sep 7:135:156022. [Abstract]
- Phytomedicine. 2024 Jul:129:155656. [Abstract]
- Phytomedicine. 2024 Jun:128:155527. [Abstract]
- Phytomedicine. 2022 Sep:104:154323. [Abstract]
- Mater Today Nano. 2024 Aug.
- NPJ Precis Oncol. 2026 Jun 17. [Abstract]
- Br J Pharmacol. 2021 Jun;178(12):2496-2515. [Abstract]
- J Transl Med. 2024 Dec 25;22(1):1147. [Abstract]
- J Transl Med. 2024 Dec 3;22(1):1095. [Abstract]
- J Transl Med. 2024 Jan 13;22(1):55. [Abstract]
- J Transl Med. 2023 Nov 21;21(1):838. [Abstract]
- Biomed Pharmacother. 2023 Oct:166:115389. [Abstract]
- Biomed Pharmacother. 2022 Apr:148:112713. [Abstract]
- Biomed Pharmacother. 2019 Sep:117:109185. [Abstract]
- Oncogene. 2026 Jun 10. [Abstract]
- MAbs. 2024 Jan-Dec;16(1):2438173. [Abstract]
- Oncogene. 2023 Oct;42(42):3113-3126. [Abstract]
- Cell Death Discov. 2026 May 25. [Abstract]
- Cell Death Discov. 2026 Apr 16;12(1):251. [Abstract]
- Cell Death Discov. 2021 May 1;7(1):89. [Abstract]
- Cell Rep. 2026 Jun 4;45(6):117496. [Abstract]
- Cell Rep. 2025 Nov 25;44(11):116476. [Abstract]
- Cell Rep. 2025 Jun 27;44(7):115925. [Abstract]
- Cell Rep. 2024 Apr 23;43(4):114088. [Abstract]
- Arch Toxicol. 2023 Dec;97(12):3209-3226. [Abstract]
- Cell Rep. 2022 Aug 16;40(7):111194. [Abstract]
- Clin Transl Med. 2026 May;16(5):e70669. [Abstract]
- Clin Transl Med. 2026 Mar;16(3):e70638. [Abstract]
- J Med Chem. 2024 Sep 12;67(17):15816-15836. [Abstract]
- Nanoscale Horiz. 2025 Jun 23;10(7):1465-1477. [Abstract]
- Int J Nanomedicine. 2025 Dec 6:20:14613-14628. [Abstract]
- Int J Nanomedicine. 2025 Jun 4:20:7169-7183. [Abstract]
- Int J Nanomedicine. 2023 Jul 20:18:3989-4005. [Abstract]
- Mol Med. 2025 Apr 4;31(1):126. [Abstract]
- Elife. 2022 May 3;11:e69255. [Abstract]
- Phytother Res. 2022 Aug;36(8):3313-3324. [Abstract]
- Cell Mol Life Sci. 2024 Oct 5;81(1):417. [Abstract]
- Cell Mol Life Sci. 2021 Dec;78(23):7505-7518. [Abstract]
- JCI Insight. 2022 Nov 22;7(22):e159419. [Abstract]
- Cancer Cell Int. 2025 Oct 15;25(1):357. [Abstract]
- Transl Res. 2023 May:255:66-76. [Abstract]
- J Mater Chem B. 2023 Nov 8;11(43):10355-10361. [Abstract]
- Biochem Pharmacol. 2025 Jul 18:241:117182. [Abstract]
- Biochem Pharmacol. 2025 Jul 18:241:117183. [Abstract]
- Biochem Pharmacol. 2024 Jun:224:116234. [Abstract]
- Biochem Pharmacol. 2021 Nov:193:114813. [Abstract]
- Cell Prolif. 2021 May;54(5):e13038. [Abstract]
- Biochem Pharmacol. 2021 Jul:189:114085. [Abstract]
- Mol Cancer Ther. 2026 Jun 13. [Abstract]
- Pharmaceutics. 2025 Jul 25;17(8):967. [Abstract]
- ACS Biomater Sci Eng. 2025 Feb 10;11(2):1222-1231. [Abstract]
- J Gastroenterol. 2025 May;60(5):641-657. [Abstract]
- J Ethnopharmacol. 2026 Feb 28:357:120890. [Abstract]
- J Ethnopharmacol. 2024 Jun 28:328:118075. [Abstract]
- Chem Biol Interact. 2024 Jan 5:387:110816. [Abstract]
- Inflamm Res. 2022 Dec;71(12):1547-1557. [Abstract]
- Chem Biol Interact. 2018 Jun 25:290:44-51. [Abstract]
- Cancer Metab. 2026 Apr 11;14(1):16.
- Cells. 2026 Feb 23;15(4):383. [Abstract]
- Commun Biol. 2026 Jan 16;9(1):260. [Abstract]
- Commun Biol. 2024 Dec 3;7(1):1612. [Abstract]
- Int J Mol Sci. 2026 Mar 13;27(6):2646. [Abstract]
- Int J Oncol. 2026 Jan;68(1):10. [Abstract]
- Cell Oncol (Dordr). 2025 Jun;48(3):655-671. [Abstract]
- ACS Appl Bio Mater. 2026 Jun 1;9(11):4723-4739. [Abstract]
- ACS Appl Polym Mater. 2026 Mar 11;8(6):4031-4044.
- Eur J Pharmacol. 2025 Dec 5:1008:178303. [Abstract]
- Bioorg Chem. 2025 Sep 17:165:109010. [Abstract]
- Eur J Pharmacol. 2025 Sep 15:1003:177942. [Abstract]
- Bioorg Chem. 2025 May 29:163:108636. [Abstract]
- Eur J Pharm Sci. 2025 Jan 1:204:106969. [Abstract]
- Int J Cancer. 2024 Jul 15;155(2):324-338. [Abstract]
- Int Immunopharmacol. 2023 Oct:123:110709. [Abstract]
- Molecules. 2023 Nov 12;28(22):7552. [Abstract]
- Molecules. 2022 Oct 13;27(20):6849. [Abstract]
- RSC Adv. 2022 Oct 3;12(43):28104-28112. [Abstract]
- Cell Rep Methods. 2026 Jun 15;6(6):101339. [Abstract]
- Mol Oncol. 2026 Jun 5. [Abstract]
- J Biomed Inform. 2023 Jun:142:104383. [Abstract]
- Mol Pharm. 2021 Jul 5;18(7):2495-2506. [Abstract]
- BJU Int. 2025 Nov 3. [Abstract]
- Clin Epigenetics. 2025 May 6;17(1):77. [Abstract]
- Biomed J. 2020 Aug;43(4):368-374. [Abstract]
- J Cannabis Res. 2024 May 8;6(1):22. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2026 Aug;1872(6):168281. [Abstract]
- FASEB J. 2025 Jul 31;39(14):e70802. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2025 Apr 30:167881. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2025 Mar 31;1871(5):167814. [Abstract]
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
- Oncol Res. 2026 Jan 19;34(2):21. [Abstract]
- Transl Oncol. 2025 Dec 2:63:102624. [Abstract]
- iScience. 2025 Nov 24;28(12):114207. [Abstract]
- iScience. 2025 Apr 23;28(6):112509. [Abstract]
- Oncol Res. 2024 Nov 13;32(12):1867-1879. [Abstract]
- Transl Oncol. 2024 Jan:39:101803. [Abstract]
- iScience. 2022 Sep 6;25(10):105081. [Abstract]
- Transl Oncol. 2020 Sep;13(9):100804. [Abstract]
- Adv Ther. 2024 Jul 18.
- Sci Rep. 2025 Sep 26;15(1):33008. [Abstract]
- Sci Rep. 2024 Nov 29;14(1):29661. [Abstract]
- J Biol Chem. 2023 Aug;299(8):104984. [Abstract]
- Oncol Rep. 2022 Feb;47(2):33. [Abstract]
- Aging. 2020 Aug 28;12(16):16304-16325. [Abstract]
- J Biol Chem. 2017 Jun 2;292(22):9136-9149. [Abstract]
- ACS Infect Dis. 2025 Oct 30. [Abstract]
- Microbiol Spectr. 2025 Sep 2;13(9):e0182025. [Abstract]
- J Pharmacol Exp Ther. 2018 Oct;367(1):20-27. [Abstract]
- Bioengineering (Basel). 2025 Oct 19;12(10):1121. [Abstract]
- Cell Signal. 2025 Jun 26:111965. [Abstract]
- Heliyon. 2024 Jun 28;10(13):e33835. [Abstract]
- Heliyon. 2022 Jun 8;8(6):e09643. [Abstract]
- Med Oncol. 2025 Dec 30;43(2):107. [Abstract]
- Transl Lung Cancer Res. 2025 Jun 30;14(6):2159-2179. [Abstract]
- Transl Lung Cancer Res. 2024 Oct 31;13(10):2698-2712. [Abstract]
- Exp Cell Res. 2020 Dec 1;397(1):112335. [Abstract]
- BMC Cancer. 2025 Dec 31. [Abstract]
- Eur J Med Res. 2025 Aug 4;30(1):704. [Abstract]
- Acta Biochim Biophys Sin (Shanghai). 2021 Mar 2;53(3):317-324. [Abstract]
- PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681. [Abstract]
- Stem Cells Int. 2023 Jan 30:2023:6510571. [Abstract]
- Front Oncol. 2021 Jul 13:11:704042. [Abstract]
- J Pharm Pharmacol. 2025 Jan 23:rgae149. [Abstract]
- Mol Carcinog. 2024 Oct;63(10):1953-1966. [Abstract]
- Mol Carcinog. 2024 Apr;63(4):772-784. [Abstract]
- Int J Med Sci. 2022 Jan 4;19(2):286-298. [Abstract]
- J Pharm Biomed Anal. 2025 Nov 15:265:117063. [Abstract]
- Cancer Med. 2019 Oct;8(13):5903-5915. [Abstract]
- Naunyn Schmiedebergs Arch Pharmacol. 2019 May;392(5):615-622. [Abstract]
- Curr Issues Mol Biol. 2024 Dec 11;46(12):13951-13969. [Abstract]
- Int J Hyperthermia. 2024 Feb 12;41(1):2316085. [Abstract]
- Breast Cancer Res Treat. 2023 Jul;200(2):193-201. [Abstract]
- Mol Immunol. 2019 May:109:140-148. [Abstract]
- Discov Oncol. 2025 Jan 3;16(1):3. [Abstract]
- Am J Cancer Res. 2020 Nov 1;10(11):3896-3910. [Abstract]
- Am J Cancer Res. 2020 Apr 1;10(4):1182-1193. [Abstract]
- J Cancer Res Clin Oncol. 2024 Jul 13;150(7):348. [Abstract]
- Technol Cancer Res Treat. 2024 Jan-Dec:23:15330338241241935. [Abstract]
- Onco Targets Ther. 2020 Sep 28;13:9543-9558. [Abstract]
- Onco Targets Ther. 2019 Jun 12:12:4585-4593. [Abstract]
- Invest New Drugs. 2025 Jun;43(3):728-741. [Abstract]
- Surgery. 2024 May;175(5):1264-1275. [Abstract]
- Immun Inflamm Dis. 2023 Jun;11(6):e872. [Abstract]
- Invest New Drugs. 2022 Apr;40(2):274-289. [Abstract]
- SLAS Discov. 2018 Aug;23(7):687-696. [Abstract]
- Cancer Manag Res. 2026 Jan 21;18:1-13.
- DNA Cell Biol. 2022 Feb;41(2):116-127. [Abstract]
- Clin Transl Oncol. 2022 Nov;24(11):2231-2240. [Abstract]
- PeerJ. 2025 May 30:13:e19517. [Abstract]
- Urol Oncol. 2021 Mar;39(3):194.e1-194.e7. [Abstract]
- Anticancer Drugs. 2025 Jun 13. [Abstract]
- Oncol Lett. 2023 Sep 20;26(5):473. [Abstract]
- Oncol Lett. 2021 Aug;22(2):626. [Abstract]
- Biol Pharm Bull. 2022 Mar 1;45(3):309-315. [Abstract]
- J Pancreatol. 2023 Dec 12.
- Int J Clin Exp Pathol. 2017;10(3):3033-3042.
- bioRxiv. 2026 May 23:2026.05.20.726695. [Abstract]
- medRxiv. 2026 Apr 18.
- Autophagy Rep. 2026 Feb 13;5(1):2624259. [Abstract]
- Res Sq. 2026 Jan 9.
- SSRN. 2025 Nov 13.
- Res Sq. 2025 Oct 29.
- RSC Pharm. 2025 Oct 9.
- bioRxiv. 2025 Oct 9:2025.10.08.681217. [Abstract]
- Res Sq. 2025 Sep 7.
- bioRxiv. 2025 Sep 24.
- bioRxiv. 2025 Sep 21.
- University of Kansas. 2025.
- Res Sq. 2025 Jul 30.
- Cell Biomater. 2025 Jul 22.
- bioRxiv. 2025 April 17.
- Res Sq. 2025 Mar 26.
- bioRxiv. 2025 Mar 13:2025.03.11.642569. [Abstract]
- bioRxiv. 2025 February 22.
- bioRxiv. 2025 Jan 27:2025.01.26.634889. [Abstract]
- bioRxiv. 2025 January 02.
- Research Square Preprint. 2024 Aug 19.
- Patent. US20240344020A1
- University of Western Australia. 2024 Jul 28.
- Patent. US20240344020A1.
- Research Square Preprint. 2024 Nov 06.
- Res Sq. 2024 Sep 05.
- bioRxiv. 2024 Aug 6:2024.03.21.586169. [Abstract]
- bioRxiv. 2024 June 12.
- SSRN. 2024 Mar 14.
- Research Square Preprint. 2024 Jan 8.
- bioRxiv. 2023 Sep 5.
- Universidad de Granada. 2023 Mar 27.
- bioRxiv. 2023 Feb 28.
- University of Brescia. 2023 Feb 2.
- bioRxiv. 2023 Feb 7.
- Patent. US20220362387A1.
- Research Square Print. October 6th, 2022.
- Oxid Med Cell Longev. 2022 Sep 29;2022:3243647. [Abstract]
- Research Square Preprint. 2021 Nov.
- Patent. US20210260092A1.
- Research Square Preprint. 2021 Aug.
- ÁREA DE FARMACIA Y TECNOLOGÍA FARMACÉUTICA. DEPARTAMENTO DE INGENIERÍA. 2020 Oct.
- Eur Rev Med Pharmacol Sci. 2019 Jan;23(2):649-659. [Abstract]
- Oncotarget. 2017 Oct 6;8(52):90185-90196. [Abstract]
- Chinese Pharmacological Bulletin. 2017, 33(6): 788-792.
-
In Vivo Efficacy Study
-
Histological Imaging/Staining
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
WB
All DNA/RNA Synthesis Isoforms
More
Biological Activity
DNA synthesis[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A2780 | IC50 |
1.25 μM
Compound: GEM
|
Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 33992863] |
| A2780 | IC50 |
1.38 μM
Compound: GEM
|
Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs in hypoxic condition by MTT assay
Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs in hypoxic condition by MTT assay
|
[PMID: 33992863] |
| A549 | IC50 |
14.65 μM
Compound: GEM
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs in hypoxic condition by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs in hypoxic condition by MTT assay
|
[PMID: 33992863] |
| A549 | IC50 |
2.31 μM
Compound: GEM
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 33992863] |
| C2D cell line | IC50 |
11.9 nM
Compound: Gemzar
|
Inhibitory concentration to inhibit growth of C2D prostate cancer cell line by using MTT assay
Inhibitory concentration to inhibit growth of C2D prostate cancer cell line by using MTT assay
|
[PMID: 14971910] |
| C2G cell line | IC50 |
3.7 nM
Compound: Gemzar
|
Inhibitory concentration to inhibit growth of C2G prostate cancer cell line by using MTT assay
Inhibitory concentration to inhibit growth of C2G prostate cancer cell line by using MTT assay
|
[PMID: 14971910] |
| L02 | IC50 |
11.87 μM
Compound: GEM
|
Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 33992863] |
| L02 | IC50 |
4.51 μM
Compound: GEM
|
Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs in hypoxic condition by MTT assay
Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs in hypoxic condition by MTT assay
|
[PMID: 33992863] |
| MCF7 | IC50 |
6.35 μM
Compound: GEM
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 33992863] |
| NCI-H460 | IC50 |
2.13 nM
Compound: Gemcitabine HCl
|
Cytotoxicity against human NCI-H460 cells by MTT assay
Cytotoxicity against human NCI-H460 cells by MTT assay
|
[PMID: 19345581] |
| NCI-H460 | IC50 |
2.13 x 10-3 μM
Compound: Gemcitabine HCl
|
Cytotoxicity against human NCI-H460 cells by MTT assay
Cytotoxicity against human NCI-H460 cells by MTT assay
|
[PMID: 19345581] |
| NCI-H460 | IC50 |
2.13 μM
Compound: GemcitabineHCl
|
Cytotoxicity against human NCI-H460 cells after 3 days by MTT assay
Cytotoxicity against human NCI-H460 cells after 3 days by MTT assay
|
[PMID: 20356655] |
| TRAMP-C1A | IC50 |
9 nM
Compound: Gemzar
|
Inhibitory concentration to inhibit growth of C1A prostate cancer cell line by using MTT assay
Inhibitory concentration to inhibit growth of C1A prostate cancer cell line by using MTT assay
|
[PMID: 14971910] |
| TRAMP-C2H | IC50 |
4.7 nM
Compound: Gemzar
|
Inhibitory concentration to inhibit growth of C2H prostate cancer cell line by using MTT assay
Inhibitory concentration to inhibit growth of C2H prostate cancer cell line by using MTT assay
|
[PMID: 14971910] |
| Vero C1008 | CC50 |
23.22 μM
Compound: Gemcitabine Hydrochloride
|
CC50 determination at MOI 0.004 using CellTiter- Glo (CTG) assay, performed 3 days post-infection in Vero E6 cells
CC50 determination at MOI 0.004 using CellTiter- Glo (CTG) assay, performed 3 days post-infection in Vero E6 cells
|
10.1101/2020.03.25.008482 |
| Vero C1008 | CC50 |
23.22 μM
Compound: Gemcitabine Hydrochloride
|
CC50 determination at MOI 0.01 using CellTiter- Glo (CTG) assay, performed 3 days post-infection in Vero E6 cells
CC50 determination at MOI 0.01 using CellTiter- Glo (CTG) assay, performed 3 days post-infection in Vero E6 cells
|
10.1101/2020.03.25.008482 |
Gemcitabine Hydrochloride (purchased from MedChem Express, 0.003-1 μM; 3 days) kills both mouse and human senescent cells effectively and potently[4].
Gemcitabine Hydrochloride inhibits the growth of BxPC-3, Mia Paca-2, PANC-1, PL-45 and AsPC-1 cells with IC50s of 37.6, 42.9, 92.7, 89.3 and 131.4 nM, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Non-senescent and replication-induced senescent new born dermal fibroblasts (NBFs)
-
Concentration:0.003, 0.01, 0.03, 0.1, 0.3, 1 μM
-
Incubation Time:3 days
-
Result:Killed replication-induced senescent NBFs for 3 days with 11.0% cell viability.
Treatment of the LSL-KrasG12D/+; LSL-Trp53R172H; Pdx-1-Cre mice with either Gemcitabine (50 mg/kg, i.p.) or the combination DMAPT/Gemcitabine Hydrochloride significantly increases the median survival time by more than 30 days compared to the placebo group (254.5 or 255 days vs. 217.5 days, respectively)[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 122111-03-9
-
Appearance Solid
-
Molecular Weight 299.66
-
Formula C9H12ClF2N3O4
-
Color White to off-white
-
SMILES
O[C@H]1C(F)(F)[C@H](N2C(N=C(N)C=C2)=O)O[C@@H]1CO.Cl
-
Synonyms
LY 188011 hydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light)
Publications (290)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]2025 Dec 15;10(1):406. PMID: 41392286 -
Nat Med
Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma. [Abstract]2024 Mar;30(3):749-761. PMID: 38287168
Gemcitabine hydrochloride purchased from MedChemExpress. Usage Cited in: Nat Med. 2024 Mar;30(3):749-761. [Abstract]
The relative cell viability of shCtl-, shNDUFB8-, and shCEMIP2-transfected cells was detected by XTT assay after paclitaxel plus gemcitabine (100 nM) treatment (A+G), single-agent 5-Fu (5-FU), and the FOLFIRINOX chemotherapy cocktail [FU+IRI+OXA: 5-FU+Irinotecan (SN-38) +Oxaliplatin] for 48h.
-
Nature
2019 Oct;574(7777):264-267. PMID: 31578522 -
-
Mol Cancer
Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer. [Abstract]2024 Sep 30;23(1):215. PMID: 39350121 -
Mol Cancer
2024 Apr 29;23(1):86. PMID: 38685067
Gemcitabine hydrochloride purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2024 Apr 29;23(1):86. [Abstract]
The cell viability of the indicated T24 cells was determined after 48 h of continuous exposure to multiple concentrations of gemcitabine.
Gemcitabine hydrochloride purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2024 Apr 29;23(1):86. [Abstract]
ATR-Chk1 pathway protein levels in the indicated T24 cells treated with 20 µg/L Gemcitabine for 6 h were determined by Western blotting.
-
Mol Cancer
Organoids derived from patients provide a new opportunity for research and individualized treatment of malignant peritoneal mesothelioma. [Abstract]2024 Jan 10;23(1):12. PMID: 38200517 -
Mol Cancer
hsa_circ_0007919 induces LIG1 transcription by binding to FOXA1/TET1 to enhance the DNA damage response and promote gemcitabine resistance in pancreatic ductal adenocarcinoma. [Abstract]2023 Dec 4;22(1):195. PMID: 38044421
Gemcitabine hydrochloride purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2023 Dec 4;22(1):195. [Abstract]
CCK-8 (0.1-102.4 µM; 24 h) analysis of the sensitivity of normal and GEM-resistant PDAC cells under different concentrations of gemcitabine (GEM).
Gemcitabine hydrochloride purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2023 Dec 4;22(1):195. [Abstract]
Comet analysis of the DNA damage of GEM-resistant PDAC cells with or without hsa_circ_0007919 inhibition and of the DNA damage of PDAC cells with or without hsa_circ_0007919 overexpression under gemcitabine (GEM) treatment condition (200×).
Gemcitabine hydrochloride purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2023 Dec 4;22(1):195. [Abstract]
IF analysis of γ-H2AX accumulation in GEM-resistant PDAC cells with or without hsa_circ_0007919 inhibition and of γ-H2AX accumulation in PDAC cells with or without hsa_circ_0007919 overexpression under gemcitabine (GEM) treatment condition (1000×).
Gemcitabine hydrochloride purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2023 Dec 4;22(1):195. [Abstract]
Expression of apoptosis-related proteins in hsa_circ_0007919-inhibited gemcitabine (GEM)-resistant PDAC cells with or without LIG1 overexpression.
-
Adv Mater
Soft Extrudable Dendritic Particles with Nanostructured Tendrils for Local Adhesion and Drug Release to Bladder Cancers. [Abstract]2025 Jul 4:e2505231. PMID: 40611758 -
Adv Mater
Epigenetic Remodeling Hydrogel Patches for Multidrug-Resistant Triple-Negative Breast Cancer. [Abstract]2021 May;33(18):e2100949. PMID: 33792093 -
Cell Res
Elimination of senescent cells by β-galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice. [Abstract]2020 Jul;30(7):574-589. PMID: 32341413 -
Gastroenterology
AGR2-Dependent Nuclear Import of RNA Polymerase II Constitutes a Specific Target of Pancreatic Ductal Adenocarcinoma in the Context of Wild-Type p53. [Abstract]2021 Nov;161(5):1601-1614.e23. PMID: 34303658
Gemcitabine hydrochloride purchased from MedChemExpress. Usage Cited in: Gastroenterology. 2021 Nov;161(5):1601-1614.e23. [Abstract]
Bar graphs show the GI50 of 5-fluoruracil (48 h), irinotecan (48 h), gemcitabine (48 h), paclitaxel (48 h), and oxaliplatin (48 h) in PDAC cells in combination with bioactive hexapeptides (NTAIYY and PTTIYY) or controls (saline and NTAIYA).
-
Cancer Commun (Lond)
Simvastatin overcomes the pPCK1-pLDHA-SPRINGlac axis-mediated ferroptosis and chemo-immunotherapy resistance in AKT-hyperactivated intrahepatic cholangiocarcinoma. [Abstract]2025 May 29. PMID: 40443016 -
Nat Metab
Uridine-sensitized screening identifies demethoxy-coenzyme Q and NUDT5 as regulators of nucleotide synthesis. [Abstract]2025 Nov 13. PMID: 41233602 -
Cancer Res
N6-methyladenosine modification of FZR1 mRNA promotes gemcitabine resistance in pancreatic cancer. [Abstract]2023 Sep 15;83(18):3059-3076. PMID: 37326469 -
Hepatology
ID3 Promotes Stem Cell Features and Predicts Chemotherapeutic Response of Intrahepatic Cholangiocarcinoma. [Abstract]2019 May;69(5):1995-2012. PMID: 30520117 -
-
Nat Commun
β-Hydroxybutyrate promotes cancer metastasis through β-hydroxybutyrylation-dependent stabilization of Snail. [Abstract]2025 Jul 17;16(1):6592. PMID: 40675949 -
Nat Commun
Intrinsic temperature increase drives lipid metabolism towards ferroptosis evasion and chemotherapy resistance in pancreatic cancer. [Abstract]2024 Oct 2;15(1):8540. PMID: 39358362 -
-
Acta Pharm Sin B
A high-throughput Gaussia luciferase reporter assay for screening potential gasdermin E activators against pancreatic cancer. [Abstract]2023 Oct;13(10):4253-4272. PMID: 37799380 -
Sci Transl Med
Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma. [Abstract]2021 Jan 20;13(577):eaba7401. PMID: 33472956 -
Adv Sci (Weinh)
Inhibition of Focal Adhesion Restricts Chemoresistance in Pancreatic Cancer by Targeting SLC7A11 Mediated Ferroptosis. [Abstract]2026 Jul;13(37):e75216. PMID: 42003743 -
Adv Sci (Weinh)
2026 Feb 3:e16660. PMID: 41632021 -
Adv Sci (Weinh)
Targeting GPX4 to Induce Ferroptosis Overcomes Chemoresistance Mediated by the PAX8-AS1/GPX4 Axis in Intrahepatic Cholangiocarcinoma. [Abstract]2025 May 20:e01042. PMID: 40391780 -
Adv Sci (Weinh)
Synthetic Retinoid Sulfarotene Selectively Inhibits Tumor-Repopulating Cells of Intrahepatic Cholangiocarcinoma via Disrupting Cytoskeleton by P-Selectin/PSGL1 N-Glycosylation Blockage. [Abstract]2024 Nov 28:e2407519. PMID: 39605300 -
Adv Sci (Weinh)
A Novel 167-Amino Acid Protein Encoded by CircPCSK6 Inhibits Intrahepatic Cholangiocarcinoma Progression via IKBα Ubiquitination. [Abstract]2025 Jan 21:e2409173. PMID: 39836545 -
Adv Sci (Weinh)
Novel CAR-T Cells Specifically Targeting SIA-CIgG Demonstrate Effective Antitumor Efficacy in Bladder Cancer. [Abstract]2024 Aug 23:e2400156. PMID: 39178136 -
Adv Sci (Weinh)
Tumor Microenvironment Responsive CD8+ T Cells and Myeloid-Derived Suppressor Cells to Trigger CD73 Inhibitor AB680-Based Synergistic Therapy for Pancreatic Cancer. [Abstract]2023 Nov;10(33):e2302498. PMID: 37867243 -
Adv Sci (Weinh)
Sonodynamic Therapy of NRP2 Monoclonal Antibody-Guided MOFs@COF Targeted Disruption of Mitochondrial and Endoplasmic Reticulum Homeostasis to Induce Autophagy-Dependent Ferroptosis. [Abstract]2023 Oct;10(30):e2303872. PMID: 37661565 -
Adv Sci (Weinh)
Primary Human Pancreatic Cancer Cells Cultivation in Microfluidic Hydrogel Microcapsules for Drug Evaluation. [Abstract]2023 Apr;10(12):e2206004. PMID: 36808707 -
Adv Sci (Weinh)
Engineered EGCG-Containing Biomimetic Nanoassemblies as Effective Delivery Platform for Enhanced Cancer Therapy. [Abstract]2022 May;9(15):e2105894. PMID: 35486032 -
J Clin Invest
DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models. [Abstract]2024 Mar 7;134(10):e172716. PMID: 38451729
Gemcitabine hydrochloride purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Mar 7;134(10):e172716. [Abstract]
The given cell lines were treated with 250 nM osimertinib (Osim), 1.25 μM Etoposide (VP-16), 125 nM Doxorubicin (DXR), 5 nM Paclitaxel, 10 μM Cisplatin, 25 μM Carboplatin, 25 nM Gemcitabine, 20 nM 5-Fluorouracil (5-FU), 25 μM Cyclophosphamide, 25 μM Capecitabine, or 10 nM Vincristine alone or in combination for 3 days. Cell numbers were then measured using the SRB assay.
-
Theranostics
Endogenous glutamate determines ferroptosis sensitivity via ADCY10-dependent YAP suppression in lung adenocarcinoma. [Abstract]2021 Mar 24;11(12):5650-5674. PMID: 33897873 -
-
-
J Adv Res
The aryl hydrocarbon receptor inhibits antigen presentation to promote progression of pancreatic ductal adenocarcinoma. [Abstract]2025 Nov 5:S2090-1232(25)00874-4. PMID: 41203070 -
J Adv Res
Targeting PLOD2 induces epithelioid differentiation and improves therapeutic response in sarcomatoid renal cell carcinoma. [Abstract]2025 Oct 16:S2090-1232(25)00818-5. PMID: 41109566 -
Biomaterials
2022 Oct:289:121800. PMID: 36166893 -
J Exp Clin Cancer Res
Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis. [Abstract]2023 May 4;42(1):111. PMID: 37143164 -
J Exp Clin Cancer Res
2022 Oct 5;41(1):293. PMID: 36199122 -
J Exp Clin Cancer Res
Epigenetic activation of the elongator complex sensitizes gallbladder cancer to gemcitabine therapy. [Abstract]2021 Nov 25;40(1):373. PMID: 34823564 -
J Nanobiotechnology
IGF1 receptor-targeted black TiO2 nanoprobes for MRI-guided synergetic photothermal-chemotherapy in drug resistant pancreatic tumor. [Abstract]2022 Jul 6;20(1):315. PMID: 35794573 -
Sci Adv
Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities. [Abstract]2026 Jun 26;12(26):eadz3351. PMID: 42361179 -
Sci Adv
2024 Dec 13;10(50):eadq4274. PMID: 39661665 -
Sci Adv
Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy response. [Abstract]2024 Jul 5;10(27):eadl1197. PMID: 38959305 -
Mol Ther
Elesclomol-copper combination synergistically targets mitochondrial metabolism in cancer stem cells to overcome chemoresistance in PDAC. [Abstract]2025 Sep 10:S1525-0016(25)00732-4. PMID: 40931516 -
Redox Biol
ARID3A enhances chemoresistance of pancreatic cancer via inhibiting PTEN-induced ferroptosis. [Abstract]2024 May 17:73:103200. PMID: 38781729 -
Redox Biol
FBW7-NRA41-SCD1 axis synchronously regulates apoptosis and ferroptosis in pancreatic cancer cells. [Abstract]2021 Jan;38:101807. PMID: 33271455 -
J Control Release
A biomimetic phase-separating hydrogel potentiates local chemo-virotherapy to eradicate recurrent glioblastoma. [Abstract]2026 Jul 10:395:114990. PMID: 42097225 -
J Control Release
Enhancing chemotherapy for pancreatic cancer through efficient and sustained tumor microenvironment remodeling with a fibroblast-targeted nanosystem. [Abstract]2023 Sep:361:161-177. PMID: 37536546 -
Research (Wash D C)
Combinational Analysis of Metabolomic and O-GlcNAcylation Omics Reveals the HBP Metabolic Regulation of Chemoresistance via GFPT1/NR3C1 O-GlcNAcylation/GPX4 Axis. [Abstract]2025 Jul 30:8:0809. PMID: 40740652 -
J Exp Med
Macrophage anti-bacterial activity is controlled by adenylate kinase 4-mediated mitochondrial DNA synthesis. [Abstract]2026 Apr 6;223(4):e20250978. PMID: 41817449 -
Cell Rep Med
Syndecan-1-targeted therapeutic antibody impairs macropinocytosis and elicits antitumor immunity in pancreatic cancer. [Abstract]2026 Feb 17;7(2):102613. PMID: 41707651 -
Cell Rep Med
Drug screening in 3D microtumors reveals DDR1/2-MAPK12-GLI1 as a vulnerability in cancer-associated fibroblasts. [Abstract]2025 Sep 19:102357. PMID: 40975064 -
Cell Rep Med
CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]2025 Apr 2:102053. PMID: 40187357 -
J Immunother Cancer
Loss of Annexin A1 in macrophages restrains efferocytosis and remodels immune microenvironment in pancreatic cancer by activating the cGAS/STING pathway. [Abstract]2024 Sep 4;12(9):e009318. PMID: 39237260 -
Cell Rep Med
Targeting neoadjuvant chemotherapy-induced metabolic reprogramming in pancreatic cancer promotes anti-tumor immunity and chemo-response. [Abstract]2023 Oct 17;4(10):101234. PMID: 37852179 -
Cell Rep Med
Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study. [Abstract]2023 Feb 21;4(2):100911. PMID: 36657446 -
Pharmacol Res
2024 May 9:204:107208. PMID: 38729587 -
Mater Today Bio
Biomimetic nanomodulator reprograms glycolysis-driven immunosuppressive microenvironment to potentiate photothermal immunotherapy in cold tumors. [Abstract]2026 May 6:38:103195. PMID: 42199354 -
Clin Cancer Res
Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response (DDR) Aberrations: Preclinical and Phase 1b Results. [Abstract]2026 Jan 21. PMID: 41563386 -
Mater Today Bio
A polymeric nanovesicle delivers sulfopin and gemcitabine to remodel tumor microenvironment for enhanced chemoimmunotherapy against orthotopic pancreatic cancer. [Abstract]2025 Jul 28:34:102153. PMID: 40799994 -
-
Cancer Lett
2026 Apr 1:642:218300. PMID: 41651400 -
Cancer Lett
2025 Apr 16:217726. PMID: 40250791 -
Cancer Lett
Pentose phosphate recycling driven by Gli1 contributes to chemotherapy resistance in cancer cells. [Abstract]2025 May 28:618:217633. PMID: 40090571 -
Cancer Lett
Exploring epigenetic dynamics unveils a super-enhancer-mediated NDRG1-β-catenin axis in modulating gemcitabine resistance in pancreatic cancer. [Abstract]2024 Nov 28:605:217284. PMID: 39366545 -
Cancer Lett
2024 Apr 10:587:216696. PMID: 38331089
Gemcitabine hydrochloride purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2024 Apr 10:587:216696. [Abstract]
Endogenous LDHA was knocked out or ZDHHC9 was knocked down in SW1990 cells. Cells were then exposed to indicated concentrations of Gemcitabine hydrochloride for 72 h, and cell viability assays were performed. The IC50 of gemcitabine was calculated for each group.
-
Cancer Lett
CircPTK2/PABPC1/SETDB1 axis promotes EMT-mediated tumor metastasis and gemcitabine resistance in bladder cancer. [Abstract]2023 Feb 1:554:216023. PMID: 36436682 -
Cancer Lett
2022 Jun 28;536:215651. PMID: 35315340 -
Int J Biol Sci
YY1-induced DLEU1/miR-149-5p Promotes Malignant Biological Behavior of Cholangiocarcinoma through Upregulating YAP1/TEAD2/SOX2. [Abstract]2022 Jul 4;18(11):4301-4315. PMID: 35864972 -
-
Cell Death Dis
Targeting mitochondrial α-ketoglutarate sequestration disables dual oncogenic drivers and metabolic adaptability in pancreatic ductal adenocarcinoma. [Abstract]2026 Jun 25. PMID: 42350388 -
Cell Death Dis
PMEPA1 modulates YAP1 nuclear translocation to disrupt EMT subtypes and promote metastasis in Biliary tract cancer. [Abstract]2026 Apr 3;17(1):449. PMID: 41932868 -
Cell Death Dis
PRDM1 restricts bladder cancer progression and enhances chemosensitivity by suppressing OTUD6A-mediated deubiquitination of CDC6. [Abstract]2026 Feb 23;17(1):247. PMID: 41724787 -
Acta Biomater
2025 Aug 27:S1742-7061(25)00640-3. PMID: 40882907 -
Cell Death Dis
TGF-β1-mediated downregulation of L1CAM in pancreatic ductal adenocarcinoma drives upregulation of collagen 17A1 and MMP2, facilitating tumor invasiveness and metastasis. [Abstract]2025 Aug 6;16(1):592. PMID: 40770187
Gemcitabine hydrochloride purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Aug 6;16(1):592. [Abstract]
Kaplan–Meier curve of #354 cells subcutaneously xenografted, treated or not with Gemcitabine hydrochloride (Gem, 100 mg/kg; i.p.; biweekly for three weeks) and/or TRL (50 mg/kg; i.p.; biweekly for three weeks).
Gemcitabine hydrochloride purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Aug 6;16(1):592. [Abstract]
Gemcitabine hydrochloride (Gem, 100 mg/kg; i.p.; biweekly for three weeks). Left: Representative histological sections of xenografts derived from #354 cells. Tumor sections were stained with Hematoxylin & Eosin (H&E). S stroma; T tumor. Right: quantification of stroma content on H&E-stained sections.
-
Cell Death Dis
Targeted delivery of the PKMYT1 inhibitor RP-6306 mediates PANoptosis in pancreatic cancer via mitotic catastrophe. [Abstract]2025 Jul 15;16(1):526. PMID: 40664640 -
Cell Death Dis
DSG2 promotes pancreatic cancer stem cell maintenance via support of tumour and macrophage cellular cross-talk. [Abstract]2025 Jul 4;16(1):492. PMID: 40615400 -
Cell Death Dis
Inhibition of KLF5 promotes ferroptosis via the ZEB1/HMOX1 axis to enhance sensitivity to oxaliplatin in cancer cells. [Abstract]2025 Jan 18;16(1):28. PMID: 39827156 -
Acta Biomater
A Supramolecular Assembly Strategy for Hydrophilic Drug Delivery towards Synergistic Cancer Treatment. [Abstract]2023 Jul 1:164:407-421. PMID: 37088157 -
-
Proc Natl Acad Sci U S A
Fra-2 controls the response to the KRAS inhibitor MRTX-1133 in pancreatic ductal adenocarcinoma. [Abstract]2026 May 5;123(18):e2601788123. PMID: 42054368 -
Cell Commun Signal
Transcriptional deregulation by FOXM1-JUP signaling confers dual oncogenic drivers for pancreatic tumorigenesis and therapeutic resistance. [Abstract]2025 Nov 27;23(1):513. PMID: 41310714 -
-
Int J Biol Macromol
High-efficiency engineering of cell membrane nanovesicles with intrinsic homotypic targeting for precision cancer drug delivery. [Abstract]2025 Dec;334(Pt 1):148793. PMID: 41213369 -
-
Acta Pharmacol Sin
SMAD4 endows TGF-β1-induced highly invasive tumor cells with ferroptosis vulnerability in pancreatic cancer. [Abstract]2024 Apr;45(4):844-856. PMID: 38057506 -
Phytomedicine
Jianpi Huayu decoction exerts antitumor effects in pancreatic cancer via SCD1-mediated lipid metabolism remodeling/ferroptosis axis. [Abstract]2025 Oct 8:148:157389. PMID: 41101075 -
Phytomedicine
Hypocrellin A against intrahepatic Cholangiocarcinoma via multi-target inhibition of the PI3K-AKT-mTOR, MAPK, and STAT3 signaling pathways. [Abstract]2024 Sep 7:135:156022. PMID: 39284270 -
Phytomedicine
Huaier enhances the tumor-killing effect and reverses gemcitabine-induced stemness by suppressing FoxM1. [Abstract]2024 Jul:129:155656. PMID: 38723529 -
Phytomedicine
Moracin D suppresses cell growth and induces apoptosis via targeting the XIAP/PARP1 axis in pancreatic cancer. [Abstract]2024 Jun:128:155527. PMID: 38489888 -
Phytomedicine
2022 Sep:104:154323. PMID: 35858516 -
-
NPJ Precis Oncol
LINC00312 increases gemcitabine sensitivity in nasopharyngeal carcinoma by recruiting PABPC1 and modulating PAX5-mediated transcription of LPLUNC1. [Abstract]2026 Jun 17. PMID: 42310073 -
Br J Pharmacol
The natural product trienomycin A is a STAT3 pathway inhibitor that exhibits potent in vitro and in vivo efficacy against pancreatic cancer. [Abstract]2021 Jun;178(12):2496-2515. PMID: 33687738 -
J Transl Med
2024 Dec 25;22(1):1147. PMID: 39722009 -
J Transl Med
Doxorubicin synergizes bortezomib-induced multiple myeloma cell death by inhibiting aggresome formation and augmenting endoplasmic reticulum/Golgi stress and apoptosis. [Abstract]2024 Dec 3;22(1):1095. PMID: 39623468 -
J Transl Med
Metabolic reprogramming based on RNA sequencing of gemcitabine-resistant cells reveals the FASN gene as a therapeutic for bladder cancer. [Abstract]2024 Jan 13;22(1):55. PMID: 38218866 -
J Transl Med
LIPH contributes to glycolytic phenotype in pancreatic ductal adenocarcinoma by activating LPA/LPAR axis and maintaining ALDOA stability. [Abstract]2023 Nov 21;21(1):838. PMID: 37990271 -
Biomed Pharmacother
Wee1 inhibition by MK1775 potentiates gemcitabine through accumulated replication stress leading to apoptosis in biliary tract cancer. [Abstract]2023 Oct:166:115389. PMID: 37659202 -
Biomed Pharmacother
Heat shock factor 1 inhibition sensitizes pancreatic cancer to gemcitabine via the suppression of cancer stem cell-like properties. [Abstract]2022 Apr:148:112713. PMID: 35158144 -
Biomed Pharmacother
Enhancement of chemosensitivity by WEE1 inhibition in EGFR-TKIs resistant non-small cell lung cancer. [Abstract]2019 Sep:117:109185. PMID: 31387179 -
Oncogene
DNA replication stress and translational repression converge to drive CDK1- and caspase-dependent apoptosis in Ewing sarcoma. [Abstract]2026 Jun 10. PMID: 42270776 -
MAbs
A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer. [Abstract]2024 Jan-Dec;16(1):2438173. PMID: 39654063 -
Oncogene
CUL4B functions as a tumor suppressor in KRAS-driven lung tumors by inhibiting the recruitment of myeloid-derived suppressor cells. [Abstract]2023 Oct;42(42):3113-3126. PMID: 37653114 -
Cell Death Discov
ATP2B4 driven chromatin compaction exacerbates pancreatic cancer radiotherapy resistance. [Abstract]2026 May 25. PMID: 42185253 -
Cell Death Discov
NAT10 promotes gallbladder cancer progression by remodeling cholesterol metabolism via PCSK9 mRNA acetylation. [Abstract]2026 Apr 16;12(1):251. PMID: 41991932 -
Cell Death Discov
A redox probe screens MTHFD1 as a determinant of gemcitabine chemoresistance in cholangiocarcinoma. [Abstract]2021 May 1;7(1):89. PMID: 33934113 -
Cell Rep
Nerve-proximal tertiary lymphoid structures predict chemotherapy sensitivity in pancreatic cancer. [Abstract]2026 Jun 4;45(6):117496. PMID: 42241282 -
Cell Rep
IGF2BP2 stabilized by USP7 promotes cancer-associated fibroblast activation and attenuates gemcitabine sensitivity in PDAC. [Abstract]2025 Nov 25;44(11):116476. PMID: 41201091 -
Cell Rep
Cingulin is an RNA-binding protein promoting pancreatic cancer through enhancing importin 7-mediated phospho-ERK nuclear translocation. [Abstract]2025 Jun 27;44(7):115925. PMID: 40580477 -
Cell Rep
IFNα-induced BST2+ tumor-associated macrophages facilitate immunosuppression and tumor growth in pancreatic cancer by ERK-CXCL7 signaling. [Abstract]2024 Apr 23;43(4):114088. PMID: 38602878 -
Arch Toxicol
SIRT3-dependent mitochondrial redox homeostasis mitigates CHK1 inhibition combined with gemcitabine treatment induced cardiotoxicity in hiPSC-CMs and mice. [Abstract]2023 Dec;97(12):3209-3226. PMID: 37798514 -
Cell Rep
S-palmitoylation of PCSK9 induces sorafenib resistance in liver cancer by activating the PI3K/AKT pathway. [Abstract]2022 Aug 16;40(7):111194. PMID: 35977495 -
Clin Transl Med
Oncogenic driver and therapeutic target: Prolactin signalling axis in retroperitoneal sarcoma. [Abstract]2026 May;16(5):e70669. PMID: 42083506 -
Clin Transl Med
Multi-omic profiling defines three distinct molecular subtypes of urothelial carcinoma with implications for precision therapy. [Abstract]2026 Mar;16(3):e70638. PMID: 41804750 -
J Med Chem
Structure-Based Drug Design of 2-Amino-[1,1'-biphenyl]-3-carboxamide Derivatives as Selective PKMYT1 Inhibitors for the Treatment of CCNE1-Amplified Breast Cancer. [Abstract]2024 Sep 12;67(17):15816-15836. PMID: 39163619 -
Nanoscale Horiz
pH-Triggered delivery of pirarubicin-gemcitabine duo using polymeric nanoparticles for synergistic breast cancer therapy. [Abstract]2025 Jun 23;10(7):1465-1477. PMID: 40396269 -
Int J Nanomedicine
2025 Dec 6:20:14613-14628. PMID: 41383278 -
Int J Nanomedicine
Intravesical Tumor-Selective Mucoadhesive Hydrogel for Effective Chemotherapy In Murine Model. [Abstract]2025 Jun 4:20:7169-7183. PMID: 40491849 -
Int J Nanomedicine
Local Sustained Chemotherapy of Pancreatic Cancer Using Endoscopic Ultrasound-Guided Injection of Biodegradable Thermo-Sensitive Hydrogel. [Abstract]2023 Jul 20:18:3989-4005. PMID: 37496690 -
Mol Med
Chlorophyllin exerts synergistic anti-tumor effect with gemcitabine in pancreatic cancer by inducing cuproptosis. [Abstract]2025 Apr 4;31(1):126. PMID: 40186145 -
Elife
2022 May 3;11:e69255. PMID: 35503721 -
Phytother Res
Higher efficacy of resveratrol against advanced breast cancer organoids: A comparison with that of clinically relevant drugs. [Abstract]2022 Aug;36(8):3313-3324. PMID: 35649509 -
Cell Mol Life Sci
KLF15 suppresses stemness of pancreatic cancer by decreasing USP21-mediated Nanog stability. [Abstract]2024 Oct 5;81(1):417. PMID: 39367978 -
Cell Mol Life Sci
OncomiRs miR-106a and miR-17 negatively regulate the nucleoside-derived drug transporter hCNT1. [Abstract]2021 Dec;78(23):7505-7518. PMID: 34647142 -
JCI Insight
Augmenting chemotherapy with low-dose decitabine through an immune-independent mechanism. [Abstract]2022 Nov 22;7(22):e159419. PMID: 36227698
Gemcitabine hydrochloride purchased from MedChemExpress. Usage Cited in: JCI Insight. 2022 Nov 22;7(22):e159419. [Abstract]
Similarly, Gemcitabine hydrochloride (Gem, 150 mg/kg) + decitabine (DAC) efficacy was preserved in immune-deficient allografts in NSG mice (n = 8–9/group).
-
Cancer Cell Int
Establishment and characteristic analysis of a novel patient derived cell line of intrahepatic cholangiocarcinoma. [Abstract]2025 Oct 15;25(1):357. PMID: 41094661 -
Transl Res
Arsenic trioxide sensitizes pancreatic cancer cells to gemcitabine through downregulation of the TIMP1/PI3K/AKT/mTOR axis. [Abstract]2023 May:255:66-76. PMID: 36400307 -
J Mater Chem B
Engineered elastin-like polypeptide-based hydrogel delivering chemotherapeutics and PD-L1 antibodies for potentiated cancer immunotherapy. [Abstract]2023 Nov 8;11(43):10355-10361. PMID: 37817648 -
Biochem Pharmacol
Targeting BACH1/PSPH axis suppresses bladder cancer progression and gemcitabine resistance by downregulating S100A2 expression. [Abstract]2025 Jul 18:241:117182. PMID: 40684997 -
Biochem Pharmacol
Pitavastatin overcomes multi-drug resistance in CRC and NSCLC by targeting the NRP1-ZFX axis. [Abstract]2025 Jul 18:241:117183. PMID: 40684995 -
Biochem Pharmacol
Modulation of epithelial-mesenchymal transition by gemcitabine: Targeting ionizing radiation-induced cellular senescence in lung cancer cell. [Abstract]2024 Jun:224:116234. PMID: 38670436 -
Biochem Pharmacol
Chrysin induces autophagy-dependent ferroptosis to increase chemosensitivity to gemcitabine by targeting CBR1 in pancreatic cancer cells. [Abstract]2021 Nov:193:114813. PMID: 34673014 -
Cell Prolif
2021 May;54(5):e13038. PMID: 33793020 -
Biochem Pharmacol
TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer. [Abstract]2021 Jul:189:114085. PMID: 32522594 -
Mol Cancer Ther
Functional genomics and proteomics identify Folate Carrier SLC19A1 as a predictor of pralatrexate sensitivity in diverse T-cell lymphoma models. [Abstract]2026 Jun 13. PMID: 42295240 -
Pharmaceutics
A Dual-Payload Bispecific ADC Improved Potency and Efficacy over Single-Payload Bispecific ADCs. [Abstract]2025 Jul 25;17(8):967. PMID: 40870990 -
ACS Biomater Sci Eng
Triplicate Dynamic Cell Culture Platform for Enhanced Reproducibility in Anti-Cancer Drug Testing. [Abstract]2025 Feb 10;11(2):1222-1231. PMID: 39809465 -
J Gastroenterol
Ferroptosis- and stemness inhibition-mediated therapeutic potency of ferrous oxide nanoparticles-diethyldithiocarbamate using a co-spheroid 3D model of pancreatic cancer. [Abstract]2025 May;60(5):641-657. PMID: 39888413 -
J Ethnopharmacol
Paris polyphylla Smith var. yunnanensis-derived saponins potentiate the antitumor activity of GPX4 inhibitors. [Abstract]2026 Feb 28:357:120890. PMID: 41232632 -
J Ethnopharmacol
A metabolomics approach reveals metabolic disturbance of human cholangiocarcinoma cells after parthenolide treatment. [Abstract]2024 Jun 28:328:118075. PMID: 38513779 -
Chem Biol Interact
Targeting PKM2 improves the gemcitabine sensitivity of intrahepatic cholangiocarcinoma cells via inhibiting β-catenin signaling pathway. [Abstract]2024 Jan 5:387:110816. PMID: 38000456
Gemcitabine hydrochloride purchased from MedChemExpress. Usage Cited in: Chem Biol Interact. 2024 Jan 5:387:110816. [Abstract]
The impact of PKM2 knockdown on gemcitabine sensitivity in ICC cells was assessed by CCK-8 assays. The cells were exposed to Gemcitabine hydrochloride (0.01-100 μM) for a duration of 72 h.
-
Inflamm Res
C/EBPβ enhances immunosuppression activity of myeloid-derived suppressor cells by a P300-mediated acetylation modification. [Abstract]2022 Dec;71(12):1547-1557. PMID: 36301341 -
Chem Biol Interact
Licoricidin enhances gemcitabine-induced cytotoxicity in osteosarcoma cells by suppressing the Akt and NF-κB signal pathways. [Abstract]2018 Jun 25:290:44-51. PMID: 29782821
Gemcitabine hydrochloride purchased from MedChemExpress. Usage Cited in: Chem Biol Interact. 2018 Jun 25:290:44-51. [Abstract]
U2OS and MG-63 cells are treated with Gemcitabine, Licoricidin, or Gemcitabine+Licoricidin for 24 h, followed by the determination of active caspse-3 protein level using western blot. Cells without treatment are used as Control.
-
-
Cells
A Comprehensive Adenoid Cystic Carcinoma-Derived Organoid Platform for Disease Modeling and Drug Screening Captures Interpatient Heterogeneity. [Abstract]2026 Feb 23;15(4):383. PMID: 41744826 -
Commun Biol
Targeting PAK4 promotes Gemcitabine-induced pyroptosis in pancreatic cancer via NLRP1/caspase-3/GSDME axis. [Abstract]2026 Jan 16;9(1):260. PMID: 41540224 -
Commun Biol
Development and validation of the Normalized Organoid Growth Rate (NOGR) metric in brightfield imaging-based assays. [Abstract]2024 Dec 3;7(1):1612. PMID: 39627437 -
Int J Mol Sci
LRRC8A Inhibition Overcomes Chemoresistance by Downregulating MRP3 and CYP3A4 in the 3D Spheroid Model of Human Breast Cancer Cells. [Abstract]2026 Mar 13;27(6):2646. PMID: 41898509 -
Int J Oncol
Discovery of the late autophagy inhibitor FZU‑0045‑053 and its anti‑breast cancer and immunomodulatory effects. [Abstract]2026 Jan;68(1):10. PMID: 41312734 -
Cell Oncol (Dordr)
LPA released from dying cancer cells after chemotherapy inactivates Hippo signaling and promotes pancreatic cancer cell repopulation. [Abstract]2025 Jun;48(3):655-671. PMID: 39903418 -
ACS Appl Bio Mater
Amphiphilic Glycopolymer Nanoparticles for pH-Responsive Paclitaxel Delivery and Enhanced Efficacy in Pancreatic Ductal Adenocarcinoma Therapy. [Abstract]2026 Jun 1;9(11):4723-4739. PMID: 42138136 -
-
Eur J Pharmacol
Doxorubicin-mediated retardation of aggresome formation enhances Carfilzomib-induced cell death synergistically by augmenting ER stress and proapoptotic signaling. [Abstract]2025 Dec 5:1008:178303. PMID: 41183585 -
Bioorg Chem
Usenamine A, an RGS2 inhibitor, exerts anti-NSCLC activity and enhances cytotoxicity of gemcitabine by inducing ER stress and Notch1-mediated autophagy. [Abstract]2025 Sep 17:165:109010. PMID: 40974657 -
Eur J Pharmacol
VOPP1, a determinant of the sensitivity of non-small cell lung cancer cells to NAE inhibitors. [Abstract]2025 Sep 15:1003:177942. PMID: 40651787 -
Bioorg Chem
Gracillin induces mitochondria-mediated apoptosis on pancreatic ductal adenocarcinoma through disruption of redox homeostasis via inhibiting NRF2/HO-1 antioxidant axis. [Abstract]2025 May 29:163:108636. PMID: 40505322 -
Eur J Pharm Sci
In vitro and in silico study of the synergistic anticancer effect of alpinumisoflavone with gemcitabine on pancreatic ductal adenocarcinoma through suppression of ribonucleotide reductase subunit-M1. [Abstract]2025 Jan 1:204:106969. PMID: 39577749 -
Int J Cancer
Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients. [Abstract]2024 Jul 15;155(2):324-338. PMID: 38533706 -
Int Immunopharmacol
STAT3 inhibition enhances gemcitabine sensitivity in pancreatic cancer by suppressing EMT, immune escape and inducing oxidative stress damage. [Abstract]2023 Oct:123:110709. PMID: 37515849 -
Molecules
Ionophore-Based Polymeric Sensors for Potentiometric Assay of the Anticancer Drug Gemcitabine in Pharmaceutical Formulation: A Comparative Study. [Abstract]2023 Nov 12;28(22):7552. PMID: 38005274 -
Molecules
Nardoguaianone L Isolated from Nardostachys jatamansi Improved the Effect of Gemcitabine Chemotherapy via Regulating AGE Signaling Pathway in SW1990 Cells. [Abstract]2022 Oct 13;27(20):6849. PMID: 36296442 -
RSC Adv
A novel immunochemotherapy based on immunogenicity-activated and immunosuppression-reversed biomimetic nanoparticles. [Abstract]2022 Oct 3;12(43):28104-28112. PMID: 36320259 -
Cell Rep Methods
Tumor immune microenvironment reconstitution in patient-derived organoids enables therapy modeling for NSCLC. [Abstract]2026 Jun 15;6(6):101339. PMID: 42134319 -
Mol Oncol
Patient therapy outcome modeling in cancer organoids is improved by cancer-associated fibroblasts and organoid assembly convolution. [Abstract]2026 Jun 5. PMID: 42246237 -
J Biomed Inform
2023 Jun:142:104383. PMID: 37196989 -
Mol Pharm
Combining Gemcitabine-Loaded Macrophage-like Nanoparticles and Erlotinib for Pancreatic Cancer Therapy. [Abstract]2021 Jul 5;18(7):2495-2506. PMID: 34078087 -
BJU Int
Drug-releasing intravesical floating technology for sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer. [Abstract]2025 Nov 3. PMID: 41178321 -
Clin Epigenetics
Investigating the mechanisms by which low NAT1 expression in tumor cells contributes to chemo-resistance in colorectal cancer. [Abstract]2025 May 6;17(1):77. PMID: 40329330 -
Biomed J
2020 Aug;43(4):368-374. PMID: 32563698 -
J Cannabis Res
Cannabidiol's cytotoxicity in pancreatic cancer is induced via an upregulation of ceramide synthase 1 and ER stress. [Abstract]2024 May 8;6(1):22. PMID: 38720356 -
Biochim Biophys Acta Mol Basis Dis
Targeted inhibition of the H3K27ac/OGT/O-GlcNAcylation axis to overcome gemcitabine-induced chemotherapy resistance in bladder cancer. [Abstract]2026 Aug;1872(6):168281. PMID: 42069092 -
FASEB J
VGF-Derived TLQP-21 Ameliorates Tumor Progression, Pain, and Depression-Like Behaviors in an Orthotopic Mouse Model of Pancreatic Ductal Adenocarcinoma. [Abstract]2025 Jul 31;39(14):e70802. PMID: 40654186 -
Biochim Biophys Acta Mol Basis Dis
2025 Apr 30:167881. PMID: 40316058 -
Biochim Biophys Acta Mol Basis Dis
Triiodothyronine promotes the proliferation and chemoresistance of cholangiocarcinoma cells via HIF-1α/Glut1-stimulated glycolysis. [Abstract]2025 Mar 31;1871(5):167814. PMID: 40168755 -
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
Oncol Res
The FN1-ITGB4 Axis Drives Acquired Chemoresistance in Bladder Cancer by Activating FAK Signaling. [Abstract]2026 Jan 19;34(2):21. PMID: 41613793 -
Transl Oncol
The CHPT-pSTAT3-SLC7A11 signaling axis controls progression and ferroptosis susceptibility of pancreatic cancer. [Abstract]2025 Dec 2:63:102624. PMID: 41337814 -
iScience
2025 Nov 24;28(12):114207. PMID: 41488371 -
iScience
Utidelone suppresses PDAC growth and enhances gemcitabine therapy by inducing immunogenic cell death. [Abstract]2025 Apr 23;28(6):112509. PMID: 40530421 -
Oncol Res
LncRNA AFAP1-AS1 exhibits oncogenic characteristics and promotes gemcitabine-resistance of cervical cancer cells through miR-7-5p/EGFR axis. [Abstract]2024 Nov 13;32(12):1867-1879. PMID: 39574469 -
Transl Oncol
Cell surface GRP78-directed CAR-T cells are effective at treating human pancreatic cancer in preclinical models. [Abstract]2024 Jan:39:101803. PMID: 37897831 -
iScience
Multiomic characterization and drug testing establish circulating tumor cells as an ex vivo tool for personalized medicine. [Abstract]2022 Sep 6;25(10):105081. PMID: 36204272 -
Transl Oncol
Low Expression of Smurf1 Enhances the Chemosensitivity of Human Colorectal Cancer to Gemcitabine and Cisplatin in Patient-Derived Xenograft Models. [Abstract]2020 Sep;13(9):100804. PMID: 32512228 -
-
Sci Rep
Identification of cytotoxic constituents from Siegesbeckiae Herba and network pharmacology prediction of their anti-pancreatic cancer mechanisms. [Abstract]2025 Sep 26;15(1):33008. PMID: 41006588 -
Sci Rep
Biological and genetic characterization of a newly established human primary multidrug-resistant distal cholangiocarcinoma cell line, CBC3T-6. [Abstract]2024 Nov 29;14(1):29661. PMID: 39613883 -
J Biol Chem
Vpx requires active cellular dNTP biosynthesis to effectively counteract the anti-lentivirus activity of SAMHD1 in macrophages. [Abstract]2023 Aug;299(8):104984. PMID: 37390988 -
Oncol Rep
Berberine enhances gemcitabine‑induced cytotoxicity in bladder cancer by downregulating Rad51 expression through inactivating the PI3K/Akt pathway. [Abstract]2022 Feb;47(2):33. PMID: 34935059 -
Aging
SP1-induced HOXD-AS1 promotes malignant progression of cholangiocarcinoma by regulating miR-520c-3p/MYCN. [Abstract]2020 Aug 28;12(16):16304-16325. PMID: 32857725 -
J Biol Chem
Physical interaction between human ribonucleotide reductase large subunit and thioredoxin increases colorectal cancer malignancy. [Abstract]2017 Jun 2;292(22):9136-9149. PMID: 28411237
Gemcitabine hydrochloride purchased from MedChemExpress. Usage Cited in: J Biol Chem. 2017 Jun 2;292(22):9136-9149. [Abstract]
The plate clone formation of SW480 and SW620 cells with Gemcitabine (8 nM in SW480 and 16 nM in SW620) and/or PX-12 (4 μM in SW480 and 8 μM in SW620).
-
ACS Infect Dis
Targeting the Rift Valley Fever Virus Polymerase: Resistance Mechanisms and Structural Insights. [Abstract]2025 Oct 30. PMID: 41166549 -
Microbiol Spectr
Survival mechanism of pancreatic tumor bacteria and their ability to metabolize chemotherapy drugs. [Abstract]2025 Sep 2;13(9):e0182025. PMID: 40792508 -
J Pharmacol Exp Ther
Metabolic Mechanisms and a Rational Combinational Application of Carboxyamidotriazole in Fighting Pancreatic Cancer Progression after Chemotherapy. [Abstract]2018 Oct;367(1):20-27. PMID: 30002095 -
Bioengineering (Basel)
Precision Oncology for High-Grade Gliomas: A Tumor Organoid Model for Adjuvant Treatment Selection. [Abstract]2025 Oct 19;12(10):1121. PMID: 41155119 -
Cell Signal
Circ_0084927 promotes progression of intrahepatic cholangiocarcinoma by sponging miR-4725-5p to activate the PDPK1/AKT/mTOR signaling pathway. [Abstract]2025 Jun 26:111965. PMID: 40581264 -
Heliyon
OIP5-AS1 enhances the malignant characteristics and resistance to chemotherapy of pancreatic cancer cells by targeting miR-30d-5p/MARCH8. [Abstract]2024 Jun 28;10(13):e33835. PMID: 39050450 -
Heliyon
Association between TOP2A, RRM1, HER2, ERCC1 expression and response to chemotherapy in patients with non-muscle invasive bladder cancer. [Abstract]2022 Jun 8;8(6):e09643. PMID: 35711974 -
Med Oncol
Derazantinib enhances gemcitabine efficacy in PDAC by attenuating the NF-κB and MAPK pathways to suppress MUC5AC expression. [Abstract]2025 Dec 30;43(2):107. PMID: 41467942 -
Transl Lung Cancer Res
Development of a 3D-3 co-culture microbead consisting of cancer-associated fibroblasts and human umbilical vein endothelial cells for the anti-tumor drug assessment of lung cancer. [Abstract]2025 Jun 30;14(6):2159-2179. PMID: 40673102 -
Transl Lung Cancer Res
Construction of a lung cancer 3D culture model based on alginate/gelatin micro-beads for drug evaluation. [Abstract]2024 Oct 31;13(10):2698-2712. PMID: 39507032 -
Exp Cell Res
2020 Dec 1;397(1):112335. PMID: 33132134 -
BMC Cancer
Individualized drug screening in cholangiocarcinoma using organoid models and patient-derived tumor xenograft. [Abstract]2025 Dec 31. PMID: 41469951 -
Eur J Med Res
Long non-coding RNA NORAD serves as a promoter of oncogenesis and inhibits ferroptosis via miR-144-3p-mTOR-ferritinophagy axis in cancer. [Abstract]2025 Aug 4;30(1):704. PMID: 40760677 -
Acta Biochim Biophys Sin (Shanghai)
Epidermal growth factor receptor promotes tumor progression and contributes to gemcitabine resistance in osteosarcoma. [Abstract]2021 Mar 2;53(3):317-324. PMID: 33432347 -
PLoS Negl Trop Dis
Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti. [Abstract]2019 Aug 20;13(8):e0007681. PMID: 31430351 -
Stem Cells Int
Extracellular Vesicle-Loaded Oncogenic lncRNA NEAT1 from Adipose-Derived Mesenchymal Stem Cells Confers Gemcitabine Resistance in Pancreatic Cancer via miR-491-5p/Snail/SOCS3 Axis. [Abstract]2023 Jan 30:2023:6510571. PMID: 36762032 -
Front Oncol
Patient-Derived Xenograft Models for Intrahepatic Cholangiocarcinoma and Their Application in Guiding Personalized Medicine. [Abstract]2021 Jul 13:11:704042. PMID: 34327143 -
J Pharm Pharmacol
Calothrixin B by docking JAK2 is a potential therapeutic inhibitor for pancreatic ductal adenocarcinoma. [Abstract]2025 Jan 23:rgae149. PMID: 39847514 -
Mol Carcinog
YAP-LAMB3 axis dictates cellular resistance of pancreatic ductal adenocarcinoma cells to gemcitabine. [Abstract]2024 Oct;63(10):1953-1966. PMID: 39016677 -
Mol Carcinog
Liensinine inhibits progression of intrahepatic cholangiocarcinoma by regulating TGF-β1 /P-smad3 signaling through HIF-1a. [Abstract]2024 Apr;63(4):772-784. PMID: 38289159 -
Int J Med Sci
Gemcitabine and XCT790, an ERRα inverse agonist, display a synergistic anticancer effect in pancreatic cancer. [Abstract]2022 Jan 4;19(2):286-298. PMID: 35165514 -
J Pharm Biomed Anal
Integrated network pharmacology and metabolomics to investigate the effect and mechanism of nitidine chloride against cholangiocarcinoma. [Abstract]2025 Nov 15:265:117063. PMID: 40652810 -
Cancer Med
Hexokinase 2 dimerization and interaction with voltage-dependent anion channel promoted resistance to cell apoptosis induced by gemcitabine in pancreatic cancer. [Abstract]2019 Oct;8(13):5903-5915. PMID: 31426130 -
Naunyn Schmiedebergs Arch Pharmacol
S-Adenosylmethionine synergistically enhances the antitumor effect of gemcitabine against pancreatic cancer through JAK2/STAT3 pathway. [Abstract]2019 May;392(5):615-622. PMID: 30683944
Gemcitabine hydrochloride purchased from MedChemExpress. Usage Cited in: Naunyn Schmiedebergs Arch Pharmacol. 2019 May;392(5):615-622. [Abstract]
The expression level of p-JAK2, p-STAT3, Bcl-XL, and Mcl-1 in PANC-1 cells is detected by western blot analysis and is all down-regulated in the treatment groups.
-
Curr Issues Mol Biol
Transcriptomic Profiling of Carboplatin- and Paclitaxel-Resistant Lung Adenocarcinoma Cells Reveals CSF3 as a Potential Biomarker for the Carboplatin Plus Paclitaxel Doublet Regimens. [Abstract]2024 Dec 11;46(12):13951-13969. PMID: 39727962 -
Int J Hyperthermia
Validation of hyperthermia as an enhancer of chemotherapeutic efficacy: insights from a bladder cancer organoid model. [Abstract]2024 Feb 12;41(1):2316085. PMID: 38346911 -
Breast Cancer Res Treat
2023 Jul;200(2):193-201. PMID: 37204665 -
Mol Immunol
RS 504393 inhibits M-MDSCs recruiting in immune microenvironment of bladder cancer after gemcitabine treatment. [Abstract]2019 May:109:140-148. PMID: 30951933 -
Discov Oncol
The molecular mechanism of gemcitabine in inhibiting the HIF-1α/VEGFB/FGF2/FGFR1 signaling pathway for ovarian cancer treatment. [Abstract]2025 Jan 3;16(1):3. PMID: 39752011 -
Am J Cancer Res
MOB1A regulates glucose deprivation-induced autophagy via IL6-STAT3 pathway in gallbladder carcinoma. [Abstract]2020 Nov 1;10(11):3896-3910. PMID: 33294275 -
Am J Cancer Res
Abrogation of ARF6 promotes RSL3-induced ferroptosis and mitigates gemcitabine resistance in pancreatic cancer cells. [Abstract]2020 Apr 1;10(4):1182-1193. PMID: 32368394 -
J Cancer Res Clin Oncol
Targeting CD73 limits tumor progression and enhances anti-tumor activity of anti-PD-1 therapy in intrahepatic cholangiocarcinoma. [Abstract]2024 Jul 13;150(7):348. PMID: 39002018 -
Technol Cancer Res Treat
Combined OLA1 and CLEC3B Gene Is a Prognostic Signature for Hepatocellular Carcinoma and Impact Tumor Progression. [Abstract]2024 Jan-Dec:23:15330338241241935. PMID: 38564315 -
Onco Targets Ther
Targeted Inhibition of P4HB Promotes Cell Sensitivity to Gemcitabine in Urothelial Carcinoma of the Bladder. [Abstract]2020 Sep 28;13:9543-9558. PMID: 33061438 -
Onco Targets Ther
Harmine suppresses the proliferation of pancreatic cancer cells and sensitizes pancreatic cancer to gemcitabine treatment. [Abstract]2019 Jun 12:12:4585-4593. PMID: 31354292 -
Invest New Drugs
A novel CDK4 inhibitor for myeloid protection in chemotherapy-treated triple-negative breast Cancer. [Abstract]2025 Jun;43(3):728-741. PMID: 40478388 -
Surgery
CPT1B maintains redox homeostasis and inhibits ferroptosis to induce gemcitabine resistance via the KEAP1/NRF2 axis in pancreatic cancer. [Abstract]2024 May;175(5):1264-1275. PMID: 38302326 -
Immun Inflamm Dis
Th17/Treg balance is regulated by myeloid-derived suppressor cells in experimental autoimmune myocarditis. [Abstract]2023 Jun;11(6):e872. PMID: 37382257 -
Invest New Drugs
Ad-VT enhances the sensitivity of chemotherapy-resistant lung adenocarcinoma cells to gemcitabine and paclitaxel in vitro and in vivo. [Abstract]2022 Apr;40(2):274-289. PMID: 34981275 -
SLAS Discov
A Multiplexed Screening Assay to Evaluate Chemotherapy-Induced Myelosuppression Using Healthy Peripheral Blood and Bone Marrow. [Abstract]2018 Aug;23(7):687-696. PMID: 29865911 -
-
DNA Cell Biol
The Role of Ferroptosis Signature in Overall Survival and Chemotherapy of Pancreatic Adenocarcinoma. [Abstract]2022 Feb;41(2):116-127. PMID: 34898275 -
Clin Transl Oncol
Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism. [Abstract]2022 Nov;24(11):2231-2240. PMID: 35852680 -
PeerJ
PLA2G16 expression predicts prognosis and gemcitabine sensitivity in patients with pancreatic cancer. [Abstract]2025 May 30:13:e19517. PMID: 40458552 -
Urol Oncol
A polymeric paste-drug formulation for local treatment of upper tract urothelial carcinoma. [Abstract]2021 Mar;39(3):194.e1-194.e7. PMID: 33250343 -
Anticancer Drugs
α-Asarone attenuates tumor-associated macrophages-induced gemcitabine resistance in pancreatic carcinoma via the transforming growth factor-beta 1/growth factor independent 1 axis. [Abstract]2025 Jun 13. PMID: 40511788 -
Oncol Lett
Identification of immunogenic cell death‑related prognostic signatures in pancreatic cancer. [Abstract]2023 Sep 20;26(5):473. PMID: 37809045 -
Oncol Lett
MicroRNA-203-3p inhibits the proliferation, invasion and migration of pancreatic cancer cells by downregulating fibroblast growth factor 2. [Abstract]2021 Aug;22(2):626. PMID: 34267818 -
Biol Pharm Bull
Synergistic Effect of Baculovirus-Mediated Endostatin and Angiostatin Combined with Gemcitabine in Hepatocellular Carcinoma. [Abstract]2022 Mar 1;45(3):309-315. PMID: 34937830 -
-
-
bioRxiv
Ferrous Iron Accumulation Is a Hallmark and Therapeutic Vulnerability of Therapy-Induced Senescence. [Abstract]2026 May 23:2026.05.20.726695. PMID: 42239384 -
-
Autophagy Rep
2026 Feb 13;5(1):2624259. PMID: 41717449 -
-
-
-
-
bioRxiv
Integrating functional genomics and proteomics identifies Folate Carrier SLC19A1 as a predictor of pralatrexate sensitivity in T-cell lymphoma. [Abstract]2025 Oct 9:2025.10.08.681217. PMID: 41279001 -
-
-
-
-
-
-
-
-
bioRxiv
Uridine-sensitized screening identifies genes and metabolic regulators of nucleotide synthesis. [Abstract]2025 Mar 13:2025.03.11.642569. PMID: 40161720 -
-
bioRxiv
TRIP13 protects pancreatic cancer cells against intrinsic and therapy-induced DNA replication stress. [Abstract]2025 Jan 27:2025.01.26.634889. PMID: 39975297 -
-
-
-
-
-
-
-
bioRxiv
2024 Aug 6:2024.03.21.586169. PMID: 38586030 -
-
-
-
-
-
-
-
-
-
-
Oxid Med Cell Longev
High Glucose Promotes Pancreatic Ductal Adenocarcinoma Gemcitabine Resistance and Invasion through Modulating ROS/MMP-3 Signaling Pathway. [Abstract]2022 Sep 29;2022:3243647. PMID: 36211828 -
-
-
-
-
Eur Rev Med Pharmacol Sci
Reduced miR-363-3p expression in non-small cell lung cancer is associated with gemcitabine resistance via targeting of CUL4A. [Abstract]2019 Jan;23(2):649-659. PMID: 30720173 -
Oncotarget
Role of drug-dependent transporter modulation on the chemosensitivity of cholangiocarcinoma. [Abstract]2017 Oct 6;8(52):90185-90196. PMID: 29163820 -
Solvent & Solubility
DMSO : 62.5 mg/mL (208.57 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 25 mg/mL (83.43 mM; Need ultrasonic)
DMF : 2.5 mg/mL (8.34 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (6.94 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (6.94 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 25 mg/mL (83.43 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (418 KB)
- English - EN (418 KB)
- Français - FR (418 KB)
- Deutsch - DE (418 KB)
- Norwegian - NO (418 KB)
- Español - ES (418 KB)
- Swedish - SV (418 KB)
- Italian - IT (418 KB)
- Korean - KR (418 KB)
- Portuguese - PT (418 KB)
-
Handling Instructions (2659 KB)
References
[1]. Wang H, et al. Enhanced efficacy of Gemcitabine by indole-3-carbinol in pancreatic cell lines: the role of human equilibrativenucleoside transporter 1. Anticancer Res. 2011 Oct;31(10):3171-80 [Content Brief]
[2]. Gagnadoux F, et al. Safety of pulmonary administration of gemcitabine in rats. J Aerosol Med. 2005 Summer;18(2):198-206 [Content Brief]
[3]. Lou M, et al. Physical interaction between human ribonucleotide reductase large subunit and thioredoxin increases colorectal cancer malignancy. J Biol Chem. 2017 Jun 2;292(22):9136-9149. [Content Brief]
[4]. Yip-Schneider MT, et al. Dimethylaminoparthenolide and Gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer. BMC Cancer. 2013 Apr 17;13:194. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMF / H2O / DMSO | 1 mM | 3.3371 mL | 16.6856 mL | 33.3712 mL | 83.4279 mL |
| 5 mM | 0.6674 mL | 3.3371 mL | 6.6742 mL | 16.6856 mL | |
| H2O / DMSO | 10 mM | 0.3337 mL | 1.6686 mL | 3.3371 mL | 8.3428 mL |
| 15 mM | 0.2225 mL | 1.1124 mL | 2.2247 mL | 5.5619 mL | |
| 20 mM | 0.1669 mL | 0.8343 mL | 1.6686 mL | 4.1714 mL | |
| 25 mM | 0.1335 mL | 0.6674 mL | 1.3348 mL | 3.3371 mL | |
| 30 mM | 0.1112 mL | 0.5562 mL | 1.1124 mL | 2.7809 mL | |
| 40 mM | 0.0834 mL | 0.4171 mL | 0.8343 mL | 2.0857 mL | |
| 50 mM | 0.0667 mL | 0.3337 mL | 0.6674 mL | 1.6686 mL | |
| 60 mM | 0.0556 mL | 0.2781 mL | 0.5562 mL | 1.3905 mL | |
| 80 mM | 0.0417 mL | 0.2086 mL | 0.4171 mL | 1.0428 mL | |
| DMSO | 100 mM | 0.0334 mL | 0.1669 mL | 0.3337 mL | 0.8343 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.